CVS Health Stock Prediction and Forecast [CVS]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 10 Oct 2025, 03:44 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for CVS Health Stock Prediction and Forecast [CVS]](https://i.ytimg.com/vi/K5rU9ncNTIg/hqdefault.jpg)
AI-generated source summary
The analysis indicates that CVS Health has been ranked as a buy candidate since August 14, 2025, with a score of 1.09. The stock has shown a gain of 15% over 40 days, resulting in a 0.38% average daily gain. It's currently in a short-term upward trend, and the analysis suggests a potential 30% change in the next three months, estimating a return range between 26% and 34%. Over a 12-month period, a 34% change is projected, resulting in a price of between 79.94 and 104.28. The stock closed at 76.74 on the last trading day, down 0.247%, with a fluctuation of 1.48%. Trading volume decreased, the stock's current price 3.09% below its 52-week high, analyst ratings are generally positive, leading the report to deem its current price undervalued and a worthwhile buy.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.